Fragile X Syndrome (FXS) Clinical Trials and Treatments

Fragile X Syndrome results from expanded CGG trinucleotide repeats in the FMR1 gene on the X chromosome, leading to gene silencing and absence of the fragile X mental retardation protein. This protein plays a critical role in regulating synaptic plasticity and dendritic spine development in the brain. Males with full mutations typically have moderate to severe intellectual disability, with IQ scores ranging from 20 to 70.

The most common symptoms of Fragile X Syndrome include Intellectual disability ranging from mild to severe, Speech and language delays, Autism spectrum behaviors including social anxiety and sensory sensitivities, Hyperactivity and attention difficulties, Distinctive physical features: large ears, long face, prominent jaw, among others. Approximately 1 in 4,000 males and 1 in 6,000 to 8,000 females. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Fragile X Syndrome from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Multiple clinical trials are investigating targeted treatments for Fragile X Syndrome, including GABA pathway modulators, mGluR5 antagonists, and approaches targeting synaptic plasticity. Promising research focuses on restoring FMRP function through gene therapy and antisense oligonucleotides.

As of October 21, 2026, no current FDA drug label names Fragile X Syndrome as a condition the drug treats.

Fragile X Syndrome is caused by variants in the FMR1 gene. Nearly all cases are a CGG repeat expansion of more than 200 repeats that silences FMR1; 55 to 200 repeats is a premutation that can expand when passed on by mothers.

It is X-linked dominant, so it affects girls as well as boys, and an affected parent has a 1 in 2 chance of passing it to each child. Approximately 1 in 4,000 males and 1 in 6,000 to 8,000 females. Genetic testing confirms the diagnosis.

Yes. Genetic testing for Fragile X Syndrome looks at the FMR1 gene. Nearly all cases are a CGG repeat expansion of more than 200 repeats that silences FMR1; 55 to 200 repeats is a premutation that can expand when passed on by mothers.

It is X-linked dominant, so it affects girls as well as boys, and an affected parent has a 1 in 2 chance of passing it to each child.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Fragile X Syndrome clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Fragile X Syndrome clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.